We are live on ! Find out more
CMMB icon

Chemomab Therapeutics
CMMB

12 hedge funds and large institutions have $2.27M invested in Chemomab Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.51% less ownership

Funds ownership: 23.01% → 21.5% (-1.5%)

45% less capital inflows, than outflows

Capital inflows: $785 | Capital outflows: $1.43K

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Moser Wealth Advisors
Moser Wealth Advisors
Washington
+$584
2
UBS Group
UBS Group
Switzerland
+$150
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$51

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$1.11K
2
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$187
3
Morgan Stanley
Morgan Stanley
New York
-$132

CMMB Hedge Fund Activity: Q3 2023 in Review

12 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2023, worth a combined $2.27M — down 32% from $3.34M a quarter earlier.

Fund positioning in CMMB was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Moser Wealth Advisors, opening a new position worth an estimated $584. The largest seller was Osaic Holdings, cutting an estimated $1.11K.

  • 12 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $2.27M of Chemomab Therapeutics stock for Q3 2023, down 32% quarter-over-quarter.
  • 2 funds opened new Chemomab Therapeutics positions in Q3 2023 and 2 closed out, a net change of 0 holders.
  • The largest Chemomab Therapeutics buyer in Q3 2023 was Moser Wealth Advisors, an estimated $584 added.
  • The largest Chemomab Therapeutics seller in Q3 2023 was Osaic Holdings, an estimated $1.11K sold.

Based on aggregated 13F filings for Q3 2023.